WallStSmart
MTD

Mettler-Toledo International Inc

NYSE: MTD · HEALTHCARE · DIAGNOSTICS & RESEARCH

$1,240.15
-1.77% today

Updated 2026-04-29

Market cap
$25.11B
P/E ratio
29.50
P/S ratio
6.24x
EPS (TTM)
$42.04
Dividend yield
—
52W range
$1,049 – $1,525
Volume
0.2M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Mettler-Toledo International Inc (MTD) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$1,240.15
Consensus
$1,448.00
+16.76%
2030 Target
—
—
DCF
$853.06
-63.25% MoS
12 analysts:
4 Buy6 Hold0 Sell

Management guidance

MTD management provided FY2026 EPS guidance of $46.90 (11.54% growth from $42.05 in FY2025) and revenue guidance of $4.27B (6.07% growth). No specific multi-year revenue targets or 2027-2030 guidance disclosed in available materials. Company raised 2026 EPS guidance post-Q4 earnings and highlighted $900M free cash flow target for 2026 with continued share repurchases.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$4,787.77
—
Base case (2030)
$2,897.86
—
Bear case (2030)
$1,889.91
—

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)
Revenue$3.8B$3.9B$4.0B$4.3B$4.5B$4.7B$4.9B
Revenue growth—2.2%4.0%6.1%4.9%4.5%4.3%
EPS$38.08$41.16$42.79$46.90$51.61$56.80$62.10
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$2,519.88$2,645.87$2,771.87$2,897.86

Catalysts & risks

Growth catalysts
+ Expansion of product inspection segment with new technology launches
+ Switzerland trade deal reducing tariff headwinds and supporting margin expansion
+ Continued M&A and R&D investment in high-growth bioprocessing and analytical instruments
+ Healthcare/pharma sector tailwinds from increased drug development and manufacturing efficiency demands
+ Industrial automation and smart manufacturing adoption across end markets
Key risks
- Tariff exposure and forex volatility impacting international revenues (37% non-USD revenue)
- High valuation at 29.9x P/E and 24.79x forward P/E limits upside and increases downside risk
- Sector competitive pressures from larger players (Thermo Fisher, Agilent) with greater R&D resources
- Macro uncertainty affecting capital equipment spending in pharma and industrial end markets
- Margin pressure from increased R&D spending and supply chain costs offsetting pricing power

Methodology

Mettler-Toledo International Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.